Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Patrick Harrington, Hugues de Lavallade, Katie J. Doores, Amy O’Reilly, Jeffrey Seow, Carl Graham, Thomas Lechmere, Deepti Radia, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto‐García, Jennifer O’Sullivan, Kavita Raj, Shahram Kordasti, Michael H. Malim, Claire Harrison, Donal P. McLornan
Topics & Concepts
AntibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Messenger RNAMedicineCoronavirus disease 2019 (COVID-19)Antibody responseAntibody therapyImmunologyBiologyCancer researchGeneGeneticsMonoclonal antibodyInternal medicineInfectious disease (medical specialty)DiseaseMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsMast cells and histamine